A corporate venture capital arm of a global pharmaceutical with headquarters in Western Europe can invest up to $5m to a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.
Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.
The firm prefers to work with management teams with a track record in the space and a strong business plan.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply